应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
FUSN Fusion Pharmaceuticals Inc.
停牌 12-18 18:09:00 EST
21.55
+0.00
0.00%
最高
21.55
最低
21.55
成交量
0.00
今开
21.55
昨收
21.55
日振幅
0.00%
总市值
18.33亿
流通市值
13.27亿
总股本
8,506万
成交额
1.31亿
换手率
0.00%
流通股本
6,158万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
隔夜美股全复盘(3.20)| 三大股指集体收涨,黄仁勋看好全球数据中心每年2500亿美元市场
格隆汇 · 03-20
隔夜美股全复盘(3.20)| 三大股指集体收涨,黄仁勋看好全球数据中心每年2500亿美元市场
Fusion Pharmaceuticals Inc.股价拉升96.99% 市值涨14.72亿美元
自选股智能写手 · 03-19
Fusion Pharmaceuticals Inc.股价拉升96.99% 市值涨14.72亿美元
今日优惠-合并与收购
Reuters · 03-19
今日优惠-合并与收购
阿斯利康(AZN.US)溢价97%收购肿瘤药企Fusion(FUSN.US) 涉资达24亿美元
阿斯达克财经 · 03-19
阿斯利康(AZN.US)溢价97%收购肿瘤药企Fusion(FUSN.US) 涉资达24亿美元
Fusion Pharmaceuticals盘前飙涨94% 阿斯利康拟溢价近一倍收购
市场资讯 · 03-19
Fusion Pharmaceuticals盘前飙涨94% 阿斯利康拟溢价近一倍收购
盘前异动 | 比特币概念股大跌,MicroStrategy跌9%;阿斯利康溢价近一倍收购,FUSN暴涨94%
老虎资讯综合 · 03-19
盘前异动 | 比特币概念股大跌,MicroStrategy跌9%;阿斯利康溢价近一倍收购,FUSN暴涨94%
美股异动 | FUSN暴涨94%,阿斯利康溢价近一倍收购该公司
智通财经 · 03-19
美股异动 | FUSN暴涨94%,阿斯利康溢价近一倍收购该公司
溢价近一倍!阿斯利康将以20亿美元现金收购Fusion Pharmaceuticals
智通财经 · 03-19
溢价近一倍!阿斯利康将以20亿美元现金收购Fusion Pharmaceuticals
阿斯利康以多至24亿美元收购Fusion Pharmaceuticals
界面 · 03-19
阿斯利康以多至24亿美元收购Fusion Pharmaceuticals
Fusion Pharmaceuticals Inc.盘中异动 股价大涨5.01%
自选股智能写手 · 03-18
Fusion Pharmaceuticals Inc.盘中异动 股价大涨5.01%
Fusion Pharmaceuticals Inc.盘中异动 急速上涨5.05%报10.40美元
自选股智能写手 · 03-07
Fusion Pharmaceuticals Inc.盘中异动 急速上涨5.05%报10.40美元
Fusion Pharmaceuticals Inc.盘中异动 早盘股价大跌5.05%
自选股智能写手 · 03-07
Fusion Pharmaceuticals Inc.盘中异动 早盘股价大跌5.05%
Fusion Pharmaceuticals Inc.盘中异动 大幅跳水5.19%报10.23美元
自选股智能写手 · 03-06
Fusion Pharmaceuticals Inc.盘中异动 大幅跳水5.19%报10.23美元
Fusion Pharmaceuticals Inc.盘中异动 早盘股价大涨5.59%报12.66美元
自选股智能写手 · 03-04
Fusion Pharmaceuticals Inc.盘中异动 早盘股价大涨5.59%报12.66美元
Fusion Pharmaceuticals Inc盘中异动 快速跳水5.93%
自选股智能写手 · 02-27
Fusion Pharmaceuticals Inc盘中异动 快速跳水5.93%
Fusion Pharmaceuticals Inc盘中异动 早盘股价大涨5.78%报12.84美元
自选股智能写手 · 02-26
Fusion Pharmaceuticals Inc盘中异动 早盘股价大涨5.78%报12.84美元
Fusion Pharmaceuticals Inc盘中异动 下午盘股价大跌5.21%报12.37美元
自选股智能写手 · 02-24
Fusion Pharmaceuticals Inc盘中异动 下午盘股价大跌5.21%报12.37美元
Fusion Pharmaceuticals Inc盘中异动 快速跳水5.19%报12.76美元
自选股智能写手 · 02-22
Fusion Pharmaceuticals Inc盘中异动 快速跳水5.19%报12.76美元
Fusion Pharmaceuticals Inc盘中异动 股价大涨5.11%报12.75美元
自选股智能写手 · 02-20
Fusion Pharmaceuticals Inc盘中异动 股价大涨5.11%报12.75美元
Fusion Pharmaceuticals Inc盘中异动 大幅上涨5.10%报11.74美元
自选股智能写手 · 02-16
Fusion Pharmaceuticals Inc盘中异动 大幅上涨5.10%报11.74美元
加载更多
公司概况
公司名称:
Fusion Pharmaceuticals Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Fusion Pharmaceuticals Inc.根据安大略商业公司法的法律于2014年12月成立。该公司是一家临床阶段的肿瘤学公司,致力于开发下一代放射性药物作为精密药物。该公司已经开发了他们的Targeted Alpha疗法(TAT)平台,以及他们专有的Fast-Clear连接器技术,使他们能够将发射α粒子的同位素与抗体和其他靶向分子连接起来,以选择性地将alpha粒子有效载荷传递到肿瘤上。他们的TAT平台以对α发射放射性药物的基本生物学的研究和见识以及目标识别,候选物生成,制造和供应链以及成像诊断开发方面的差异化能力为基础。
发行价格:
--
{"stockData":{"symbol":"FUSN","market":"US","secType":"STK","nameCN":"Fusion Pharmaceuticals Inc.","latestPrice":21.55,"timestamp":1717444800000,"preClose":21.55,"halted":3,"volume":0,"delay":0,"floatShares":61576601,"shares":85059965,"eps":-1.426253,"marketStatus":"停牌","marketStatusCode":4,"change":0,"latestTime":"12-18 18:09:00 EST","open":21.55,"high":21.55,"low":21.55,"amount":130901959.304311,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.426253,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1734570000000},"adr":0,"listingDate":1593144000000,"adjPreClose":21.55,"volumeRatio":0},"requestUrl":"/m/hq/s/FUSN","defaultTab":"news","newsList":[{"id":"2420736325","title":"隔夜美股全复盘(3.20)| 三大股指集体收涨,黄仁勋看好全球数据中心每年2500亿美元市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2420736325","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2420736325?lang=zh_cn&edition=full","pubTime":"2024-03-20 08:18","pubTimestamp":1710893884,"startTime":"0","endTime":"0","summary":"三大股指集体收涨,黄仁勋看好全球数据中心每年2500亿美元市场","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/709241","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["AZN","LU0053671581.USD","LU0795875169.SGD","LU1244550221.USD","LU0742534661.SGD","LU1829250122.USD","IE00BFSS7M15.SGD","IE00B775SV38.USD","LU0320765059.SGD","IE00B19Z3581.USD","LU1066053197.SGD","SG9999001440.SGD","IE00BD6J9T35.USD","LU0056508442.USD","LU0048573561.USD","LU0080751232.USD","LU0912757837.SGD","NVDA","LU0444971666.USD","IE0034235188.USD","LU0109394709.USD","LU0097036916.USD","LU0234570918.USD","FUSN","BK4592","LU0971096721.USD","LU1363072403.SGD","LU1032466523.USD","SMCI","LU0640476718.USD","LU0109392836.USD","LU0127658192.USD","LU0980610538.SGD","LU0289961442.SGD","LU0889566641.SGD","LU0276348264.USD","LU2133065610.SGD","LU2347655156.SGD","LU0198837287.USD","JNJ","IE00BWXC8680.SGD","LU1074936037.SGD","LU1201861249.SGD","IE00BMPRXR70.SGD","LU0149725797.USD","LU0795875086.SGD","HOOD","BRK.B","LU0234572021.USD","BK4170"],"gpt_icon":0},{"id":"2420224766","title":"Fusion Pharmaceuticals Inc.股价拉升96.99% 市值涨14.72亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2420224766","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2420224766?lang=zh_cn&edition=full","pubTime":"2024-03-19 21:30","pubTimestamp":1710855024,"startTime":"0","endTime":"0","summary":"北京时间2024年03月19日21时30分,Fusion Pharmaceuticals Inc.股票出现波动,股价快速拉升96.99%。Fusion Pharmaceuticals Inc.股票所在的生物技术行业中,整体跌幅为0.07%。Fusion Pharmaceuticals Inc.公司简介:Fusion Pharmaceuticals Inc是一家处于临床阶段的生物制药公司,专注于开发治疗癌症的α疗法。消息层面,截至21时30分,《溢价近一倍!阿斯利康将以20亿美元现金收购Fusion Pharmaceuticals》资讯为影响Fusion Pharmaceuticals Inc.的重要信息。阿斯利康将以每股21美元的价格收购Fusion,较这家美国上市公司周一的收盘价溢价逾97%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031921302587e7a0d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031921302587e7a0d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FUSN","BK4139"],"gpt_icon":0},{"id":"2420243094","title":"今日优惠-合并与收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2420243094","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2420243094?lang=zh_cn&edition=full","pubTime":"2024-03-19 18:04","pubTimestamp":1710842657,"startTime":"0","endTime":"0","summary":" 路透社3月19日 - 截至格林尼治标准时间周二9:30,以下是有关竞标、兼并、收购和处置的报道:** 蒂森克虏伯 正在评估向投资公司凯雷 出售其海洋系统部门股份的可能性,该部门负责建造海军舰艇和潜艇。** 澳大利亚博罗公司 建议投资者拒绝其最大股东Seven Group Holdings 提出的19亿,声称该要约低估了这家建筑产品集团的价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7044","LU0289739699.SGD","LU0122379950.USD","BK4139","ELV","LU1815333072.USD","LU2592432038.USD","LU1280957306.USD","SG9999001077.SGD","LU2505996681.GBP","BK4533","LU2505996509.AUD","LU0048573561.USD","LU0061474960.USD","LU0068578508.USD","FUSN","LU1057294990.SGD","LU2430703178.SGD","SGXZ23171101.USD","LU0882574055.USD","LU0266013472.USD","LU2430703251.USD","LU0957791311.USD","LU2430703095.HKD","LU0234570918.USD","LU1720051017.SGD","LU0170899867.USD","LU1670627923.USD","LU1670628061.USD","LU1548497426.USD","BK4113","LU0985489474.SGD","BK4559","KR","DRQ","BLD.AU","LU0251142724.SGD","BK4588","LU0878866978.SGD","LU1023059063.AUD","BK4154","LU1489326972.SGD","LU0557290698.USD","BK4504","LU0433182093.SGD","LU0058720904.USD","SVW.AU","LU0114720955.EUR","CG","LU0312595415.SGD"],"gpt_icon":0},{"id":"2420624875","title":"阿斯利康(AZN.US)溢价97%收购肿瘤药企Fusion(FUSN.US) 涉资达24亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2420624875","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2420624875?lang=zh_cn&edition=full","pubTime":"2024-03-19 17:39","pubTimestamp":1710841140,"startTime":"0","endTime":"0","summary":"英国药业巨擘阿斯利康提出以20亿美元现金收购临床阶段生物制药公司Fusion Pharmaceuticals,以扩大其肿瘤产品组合。阿斯利康将以每股21美元的价格收购Fusion,较这家美国上市公司周一收盘价溢价逾97%。在达到特定监管里程碑时,阿斯利康还将支付每股3美元的不可转让或有价值权,使合并交易价值达到约24亿美元。Fusion隔晚收报10.64美元,该股过去12个月累升165%,有分析师曾预测该股有潜质被收购。阿斯利康英股周二早段跌1.1%,报10,176便士。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20211209122201027_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20211209122201027_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1334643/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0109394709.USD","BK4585","AZN","BK4007","BK4139","FUSN","BK4568","LU1829250122.USD","LU0320765992.SGD","LU2236285917.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2420146782","title":"Fusion Pharmaceuticals盘前飙涨94% 阿斯利康拟溢价近一倍收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2420146782","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2420146782?lang=zh_cn&edition=full","pubTime":"2024-03-19 16:22","pubTimestamp":1710836520,"startTime":"0","endTime":"0","summary":"临床阶段生物制药公司Fusion Pharmaceuticals(FUSN.US)盘前飙涨94%,报20.65美元。消息上,阿斯利康周二表示,将以约20亿美元现金收购Fusion Pharmaceuticals,以扩大其肿瘤产品组合。阿斯利康将以每股21美元的价格收购Fusion,较这家美国上市公司周一的收盘价溢价逾97%。阿斯利康还将支付每股3美元的不可转让或有价值权,使合并交易价值达到约24亿美元。\n\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:郭明煜","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-03-19/doc-inanvyns9322058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0109394709.USD","BK4139","FUSN","LU2236285917.USD","LU1829250122.USD","BK4585","BK4568","LU0889565916.HKD","LU0320765992.SGD","AZN","BK4007"],"gpt_icon":0},{"id":"1140447176","title":"盘前异动 | 比特币概念股大跌,MicroStrategy跌9%;阿斯利康溢价近一倍收购,FUSN暴涨94%","url":"https://stock-news.laohu8.com/highlight/detail?id=1140447176","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140447176?lang=zh_cn&edition=full","pubTime":"2024-03-19 16:04","pubTimestamp":1710835490,"startTime":"0","endTime":"0","summary":"阿斯利康表示,将以约20亿美元现金收购临床阶段生物制药公司Fusion Pharmaceuticals,以扩大其肿瘤产品组合。阿斯利康将以每股21美元的价格收购Fusion,较这家美国上市公司周一的收盘价溢价逾97%。阿斯利康还将支付每股3美元的不可转让或有价值权,使合并交易价值达到约24亿美元。比特币概念股盘前大跌,MicroStrategy跌超9%、Coinbase跌超5%、Riot Platforms跌超3%。灰度ETF出现单日最大规模资金外流,推动比特币下跌。","market":"us","thumbnail":"https://static.tigerbbs.com/a7ed81b1e72df2f2f0f21497fe08eaed","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a7ed81b1e72df2f2f0f21497fe08eaed"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAN","XBTmain","BRRR","HODL","BK4139","IBIT","BK4595","BTCmain","BTCW","EBON","EZBC","FUSN",".DJI","SOUN","COIN",".IXIC","FBTC","BTCO","BK4526","MSTR","SPIR","BITB","BK4568","BITO","GBTC","AZN","DEFI"],"gpt_icon":1},{"id":"2420215327","title":"美股异动 | FUSN暴涨94%,阿斯利康溢价近一倍收购该公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2420215327","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2420215327?lang=zh_cn&edition=full","pubTime":"2024-03-19 16:01","pubTimestamp":1710835293,"startTime":"0","endTime":"0","summary":"$阿斯利康(AZN)$周二表示,将以约20亿美元现金收购临床阶段生物制药公司Fusion Pharmaceuticals,以扩大其肿瘤产品组合。阿斯利康将以每股21美元的价格收购Fusion,较这家美国上市公司周一的收盘价溢价逾97%。阿斯利康还将支付每股3美元的不可转让或有价值权,使合并交易价值达到约24亿美元。该公司表示,正在开发“下一代”放射性偶联药物(RCs)治疗癌症的Fusion将成为阿斯利康的全资子公司,并继续在加拿大和美国开展业务。阿斯利康表示,近年来,RCs已成为一种有前景的癌症治疗方式。","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1088335.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0109394709.USD","BK4139","FUSN","BK4568","AZN","LU1829250122.USD","LU0320765992.SGD","BK4585","LU2236285917.USD","LU0889565916.HKD","BK4007"],"gpt_icon":0},{"id":"1153499682","title":"溢价近一倍!阿斯利康将以20亿美元现金收购Fusion Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=1153499682","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153499682?lang=zh_cn&edition=full","pubTime":"2024-03-19 15:55","pubTimestamp":1710834925,"startTime":"0","endTime":"0","summary":"$阿斯利康(AZN)$周二表示,将以约20亿美元现金收购临床阶段生物制药公司Fusion Pharmaceuticals(FUSN.US),以扩大其肿瘤产品组合。阿斯利康将以每股21美元的价格收购Fusion,较这家美国上市公司周一的收盘价溢价逾97%。阿斯利康还将支付每股3美元的不可转让或有价值权,使合并交易价值达到约24亿美元。该公司表示,正在开发“下一代”放射性偶联药物(RCs)治疗癌症的Fusion将成为阿斯利康的全资子公司,并继续在加拿大和美国开展业务。阿斯利康表示,近年来,RCs已成为一种有前景的癌症治疗方式。","market":"us","thumbnail":"https://static.tigerbbs.com/2f492bd13fcab7e536b49f65d4a241bb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/2f492bd13fcab7e536b49f65d4a241bb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1088335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0109394709.USD","BK4139","FUSN","BK4568","AZN","LU1829250122.USD","LU0320765992.SGD","BK4585","LU2236285917.USD","LU0889565916.HKD","BK4007"],"gpt_icon":0},{"id":"2420829088","title":"阿斯利康以多至24亿美元收购Fusion Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2420829088","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2420829088?lang=zh_cn&edition=full","pubTime":"2024-03-19 15:09","pubTimestamp":1710832171,"startTime":"0","endTime":"0","summary":"生物制药公司Fusion Pharmaceuticals于3月19日宣布,公司已就被阿斯利康收购一事达成最终协议。根据最终协议的条款,阿斯利康将通过一家子公司,按照安排计划收购Fusion的全部流通股,价格为每股21美元现金,外加一项不可转让的或有价值权(CVR),即在达到特定监管里程碑时支付的每股3美元现金。预付现金部分的交易价值约为20亿美元,预付款和最大潜在或有价值付款加在一起,交易价值约为24亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240319150931791b5d96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240319150931791b5d96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FUSN","BK4007","LU0320765992.SGD","LU1829250122.USD","BK4585","AZN","BK4568","LU0109394709.USD","LU2236285917.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2420774384","title":"Fusion Pharmaceuticals Inc.盘中异动 股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420774384","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2420774384?lang=zh_cn&edition=full","pubTime":"2024-03-18 21:57","pubTimestamp":1710770272,"startTime":"0","endTime":"0","summary":"北京时间2024年03月18日21时57分,Fusion Pharmaceuticals Inc.股票出现异动,股价快速上涨5.01%。截至发稿,该股报10.49美元/股,成交量22.7724万股,换手率0.31%,振幅6.91%。Fusion Pharmaceuticals Inc.股票所在的生物技术行业中,整体跌幅为0.16%。Fusion Pharmaceuticals Inc.公司简介:Fusion Pharmaceuticals Inc是一家处于临床阶段的生物制药公司,专注于开发治疗癌症的α疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403182157527a4d7046&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403182157527a4d7046&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FUSN"],"gpt_icon":0},{"id":"2417793548","title":"Fusion Pharmaceuticals Inc.盘中异动 急速上涨5.05%报10.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2417793548","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2417793548?lang=zh_cn&edition=full","pubTime":"2024-03-07 23:14","pubTimestamp":1709824490,"startTime":"0","endTime":"0","summary":"北京时间2024年03月07日23时14分,Fusion Pharmaceuticals Inc.股票出现波动,股价急速拉升5.05%。截至发稿,该股报10.40美元/股,成交量32.4686万股,换手率0.45%,振幅4.95%。Fusion Pharmaceuticals Inc.股票所在的生物技术行业中,整体涨幅为2.42%。Fusion Pharmaceuticals Inc.公司简介:Fusion Pharmaceuticals Inc是一家处于临床阶段的生物制药公司,专注于开发治疗癌症的α疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030723145087e76fa5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030723145087e76fa5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FUSN","BK4139"],"gpt_icon":0},{"id":"2417162242","title":"Fusion Pharmaceuticals Inc.盘中异动 早盘股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417162242","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2417162242?lang=zh_cn&edition=full","pubTime":"2024-03-07 00:13","pubTimestamp":1709741583,"startTime":"0","endTime":"0","summary":"北京时间2024年03月07日00时13分,Fusion Pharmaceuticals Inc.股票出现异动,股价大幅跳水5.05%。Fusion Pharmaceuticals Inc.股票所在的生物技术行业中,整体涨幅为0.28%。其相关个股中,知临集团、Biomx Inc.、Nkgen Biotech, Inc.涨幅较大,知临集团、Biomx Inc.、Creative Medical Technology Holdings, Inc.较为活跃,换手率分别为634.93%、217.19%、188.57%,振幅较大的相关个股有知临集团、Nkgen Biotech Inc C/Wts 31/05/2028、Nkgen Biotech, Inc.,振幅分别为311.01%、255.56%、192.58%。Fusion Pharmaceuticals Inc.公司简介:Fusion Pharmaceuticals Inc是一家处于临床阶段的生物制药公司,专注于开发治疗癌症的α疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403070013037917eaad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403070013037917eaad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FUSN","BK4139"],"gpt_icon":0},{"id":"2417441017","title":"Fusion Pharmaceuticals Inc.盘中异动 大幅跳水5.19%报10.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2417441017","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2417441017?lang=zh_cn&edition=full","pubTime":"2024-03-06 01:01","pubTimestamp":1709658100,"startTime":"0","endTime":"0","summary":"北京时间2024年03月06日01时01分,Fusion Pharmaceuticals Inc.股票出现异动,股价急速跳水5.19%。Fusion Pharmaceuticals Inc.股票所在的生物技术行业中,整体跌幅为1.43%。其相关个股中,Ys Biopharma Co Ltd C/Wts 15/03/2028 、Ocean Biomedical Inc C/Wts 14/02/2028 、Ocean Biomedical, Inc.涨幅较大,Quoin Pharmaceuticals Ltd、Jaguar Health, Inc.、Ocean Biomedical, Inc.较为活跃,换手率分别为297.52%、193.52%、123.67%,振幅较大的相关个股有Ys Biopharma Co Ltd C/Wts 15/03/2028 、Ocean Biomedical Inc C/Wts 14/02/2028 、Coeptis Therapeutics Holdings Inc C/Wts 31/12/2024 ,振幅分别为70.24%、69.48%、68.86%。Fusion Pharmaceuticals Inc.公司简介:Fusion Pharmaceuticals Inc是一家处于临床阶段的生物制药公司,专注于开发治疗癌症的α疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403060101417a49bfcc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403060101417a49bfcc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FUSN","BK4139"],"gpt_icon":0},{"id":"2416142967","title":"Fusion Pharmaceuticals Inc.盘中异动 早盘股价大涨5.59%报12.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2416142967","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2416142967?lang=zh_cn&edition=full","pubTime":"2024-03-04 22:33","pubTimestamp":1709562801,"startTime":"0","endTime":"0","summary":"北京时间2024年03月04日22时33分,Fusion Pharmaceuticals Inc.股票出现异动,股价快速上涨5.59%。截至发稿,该股报12.66美元/股,成交量4.7663万股,换手率0.07%,振幅1.75%。Fusion Pharmaceuticals Inc.股票所在的生物技术行业中,整体涨幅为0.74%。Fusion Pharmaceuticals Inc.公司简介:Fusion Pharmaceuticals Inc是一家处于临床阶段的生物制药公司,专注于开发治疗癌症的α疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403042233217a495109&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403042233217a495109&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FUSN","BK4139"],"gpt_icon":0},{"id":"2414559805","title":"Fusion Pharmaceuticals Inc盘中异动 快速跳水5.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2414559805","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2414559805?lang=zh_cn&edition=full","pubTime":"2024-02-27 22:54","pubTimestamp":1709045663,"startTime":"0","endTime":"0","summary":"北京时间2024年02月27日22时54分,Fusion Pharmaceuticals Inc股票出现异动,股价急速跳水5.93%。Fusion Pharmaceuticals Inc股票所在的生物技术行业中,整体跌幅为0.68%。其相关个股中,Janux Therapeutics Inc、Viking Therapeutics Inc、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大,Scisparc Ltd、Zyversa Therapeutics Inc、Galera Therapeutics Inc较为活跃,换手率分别为339.30%、133.61%、31.16%,振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Viking Therapeutics Inc、Newamsterdam Pharma Co Nv C/Wts 22/11/2027 ,振幅分别为83.49%、50.96%、37.40%。Fusion Pharmaceuticals Inc公司简介:Fusion Pharmaceuticals Inc是一家处于临床阶段的生物制药公司,专注于开发治疗癌症的α疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402272254237a47543b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402272254237a47543b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FUSN"],"gpt_icon":0},{"id":"2414591833","title":"Fusion Pharmaceuticals Inc盘中异动 早盘股价大涨5.78%报12.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2414591833","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2414591833?lang=zh_cn&edition=full","pubTime":"2024-02-26 22:38","pubTimestamp":1708958304,"startTime":"0","endTime":"0","summary":"北京时间2024年02月26日22时38分,Fusion Pharmaceuticals Inc股票出现异动,股价快速拉升5.78%。截至发稿,该股报12.84美元/股,成交量4.4699万股,换手率0.06%,振幅5.77%。Fusion Pharmaceuticals Inc股票所在的生物技术行业中,整体涨幅为0.17%。Fusion Pharmaceuticals Inc公司简介:Fusion Pharmaceuticals Inc是一家处于临床阶段的生物制药公司,专注于开发治疗癌症的α疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402262238247914b293&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402262238247914b293&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FUSN","BK4139"],"gpt_icon":0},{"id":"2413185337","title":"Fusion Pharmaceuticals Inc盘中异动 下午盘股价大跌5.21%报12.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2413185337","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2413185337?lang=zh_cn&edition=full","pubTime":"2024-02-24 03:08","pubTimestamp":1708715294,"startTime":"0","endTime":"0","summary":"北京时间2024年02月24日03时08分,Fusion Pharmaceuticals Inc股票出现波动,股价大幅跳水5.21%。截至发稿,该股报12.37美元/股,成交量37.8408万股,换手率0.52%,振幅8.28%。Fusion Pharmaceuticals Inc股票所在的生物技术行业中,整体涨幅为0.32%。Fusion Pharmaceuticals Inc公司简介:Fusion Pharmaceuticals Inc是一家处于临床阶段的生物制药公司,专注于开发治疗癌症的α疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402240308147913f657&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402240308147913f657&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FUSN"],"gpt_icon":0},{"id":"2413471977","title":"Fusion Pharmaceuticals Inc盘中异动 快速跳水5.19%报12.76美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2413471977","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2413471977?lang=zh_cn&edition=full","pubTime":"2024-02-22 01:49","pubTimestamp":1708537777,"startTime":"0","endTime":"0","summary":"北京时间2024年02月22日01时49分,Fusion Pharmaceuticals Inc股票出现异动,股价大幅下挫5.19%。截至发稿,该股报12.76美元/股,成交量109.992万股,换手率1.52%,振幅8.40%。Fusion Pharmaceuticals Inc股票所在的生物技术行业中,整体跌幅为0.35%。Fusion Pharmaceuticals Inc公司简介:Fusion Pharmaceuticals Inc是一家处于临床阶段的生物制药公司,专注于开发治疗癌症的α疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022201493879132946&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022201493879132946&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FUSN","BK4139"],"gpt_icon":0},{"id":"2412210951","title":"Fusion Pharmaceuticals Inc盘中异动 股价大涨5.11%报12.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2412210951","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2412210951?lang=zh_cn&edition=full","pubTime":"2024-02-20 23:20","pubTimestamp":1708442415,"startTime":"0","endTime":"0","summary":"北京时间2024年02月20日23时20分,Fusion Pharmaceuticals Inc股票出现波动,股价急速拉升5.11%。Fusion Pharmaceuticals Inc股票所在的生物技术行业中,整体涨幅为0.33%。其相关个股中,Monopar Therapeutics Inc、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Tc Biopharm Plc C/Wts 10/02/2028 涨幅较大,Scisparc Ltd、Monopar Therapeutics Inc、Clearmind Medicine Inc较为活跃,换手率分别为2191.81%、410.91%、317.30%,振幅较大的相关个股有Monopar Therapeutics Inc、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Scisparc Ltd,振幅分别为198.48%、78.43%、56.90%。Fusion Pharmaceuticals Inc公司简介:Fusion Pharmaceuticals Inc是一家处于临床阶段的生物制药公司,专注于开发治疗癌症的α疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402202320157912c845&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402202320157912c845&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FUSN","BK4139"],"gpt_icon":0},{"id":"2411752970","title":"Fusion Pharmaceuticals Inc盘中异动 大幅上涨5.10%报11.74美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2411752970","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2411752970?lang=zh_cn&edition=full","pubTime":"2024-02-16 02:05","pubTimestamp":1708020316,"startTime":"0","endTime":"0","summary":"北京时间2024年02月16日02时05分,Fusion Pharmaceuticals Inc股票出现波动,股价大幅拉升5.10%。Fusion Pharmaceuticals Inc股票所在的生物技术行业中,整体涨幅为0.09%。其相关个股中,Psyence Biomedical Ltd C/Wts 25/01/2029、Tc Biopharm Plc C/Wts 10/02/2028 、Orgenesis Inc涨幅较大,Kintara Therapeutics Inc、Transcode Therapeutics Inc、Adial Pharmaceuticals Inc较为活跃,换手率分别为84.39%、55.52%、54.09%,振幅较大的相关个股有Pasithea Therapeutics Corp C/Wts 12/08/2026 、Psyence Biomedical Ltd C/Wts 25/01/2029、Neurosense Therapeutics Ltd C/Wts 10/11/2026 ,振幅分别为73.10%、67.27%、63.33%。Fusion Pharmaceuticals Inc公司简介:Fusion Pharmaceuticals Inc是一家处于临床阶段的生物制药公司,专注于开发治疗癌症的α疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402160205177a43d861&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402160205177a43d861&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FUSN","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fusionpharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":2.9325},{"period":"ytd","weight":1.2425}],"compareEarnings":[{"period":"1week","weight":0.0025},{"period":"1month","weight":0.0317},{"period":"3month","weight":0.0764},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.2804},{"period":"ytd","weight":0.2714}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Fusion Pharmaceuticals Inc.根据安大略商业公司法的法律于2014年12月成立。该公司是一家临床阶段的肿瘤学公司,致力于开发下一代放射性药物作为精密药物。该公司已经开发了他们的Targeted Alpha疗法(TAT)平台,以及他们专有的Fast-Clear连接器技术,使他们能够将发射α粒子的同位素与抗体和其他靶向分子连接起来,以选择性地将alpha粒子有效载荷传递到肿瘤上。他们的TAT平台以对α发射放射性药物的基本生物学的研究和见识以及目标识别,候选物生成,制造和供应链以及成像诊断开发方面的差异化能力为基础。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.232831},{"month":2,"riseRate":1,"avgChangeRate":0.131408},{"month":3,"riseRate":0.5,"avgChangeRate":0.146308},{"month":4,"riseRate":0.5,"avgChangeRate":-0.124248},{"month":5,"riseRate":0.5,"avgChangeRate":-0.003131},{"month":6,"riseRate":0.25,"avgChangeRate":-0.10593},{"month":7,"riseRate":0.25,"avgChangeRate":-0.143007},{"month":8,"riseRate":0.25,"avgChangeRate":-0.014692},{"month":9,"riseRate":0.25,"avgChangeRate":0.005874},{"month":10,"riseRate":0.5,"avgChangeRate":0.125937},{"month":11,"riseRate":0.5,"avgChangeRate":0.011293},{"month":12,"riseRate":0.5,"avgChangeRate":0.177754}],"exchange":"NASDAQ","name":"Fusion Pharmaceuticals Inc.","nameEN":"Fusion Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fusion Pharmaceuticals Inc.(FUSN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Fusion Pharmaceuticals Inc.(FUSN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Fusion Pharmaceuticals Inc.,FUSN,Fusion Pharmaceuticals Inc.股票,Fusion Pharmaceuticals Inc.股票老虎,Fusion Pharmaceuticals Inc.股票老虎国际,Fusion Pharmaceuticals Inc.行情,Fusion Pharmaceuticals Inc.股票行情,Fusion Pharmaceuticals Inc.股价,Fusion Pharmaceuticals Inc.股市,Fusion Pharmaceuticals Inc.股票价格,Fusion Pharmaceuticals Inc.股票交易,Fusion Pharmaceuticals Inc.股票购买,Fusion Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fusion Pharmaceuticals Inc.(FUSN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Fusion Pharmaceuticals Inc.(FUSN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}